Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
Industry, policymakers focus on AI-led regulatory harmonisation, FTAs, MSME support and market expansion as exports touch $28.29 billion till February FY26
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports
A joint position paper warns that Europe is the only major global region without a dedicated biomanufacturing initiative
Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
This marks a meaningful step in the company's continued expansion in the region
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
Subscribe To Our Newsletter & Stay Updated
